Jupiter, FL – [August 1st, 2023] – Myosin Therapeutics is pleased to announce the successful completion of key milestones in the National Institutes of Health (NIH) Blueprint Neurotherapeutics (BPN) Program for its lead compound, MT-110, which is undergoing preclinical testing as a novel therapeutic for methamphetamine use disorder. Following this achievement, the company has initiated Good Manufacturing Practice (GMP) manufacturing of MT-110 to enable filing of an Investigational New Drug (IND) application and support planned Phase 1 clinical trials.
The NIH BPN Program is a highly competitive initiative that provides funding and expert resources to accelerate the development of promising neuroscience therapeutics. Participation in this program is a testament to the innovative potential of MT-110, as the BPN program selects only a small number of cutting-edge projects from across the country. Myosin Therapeutics’ success in advancing through the milestone-based program underscores the impact MT-110 could have as the first pharmacotherapy for methamphetamine use disorder.
The achievements under the BPN Program have included extensive preclinical in vivo efficacy and safety studies in animal models, demonstrating that MT-110 effectively disrupts the motivation for methamphetamine. The IND submission is planned for Q4 2024. This crucial step brings Myosin Therapeutics closer to starting its Phase 1 clinical trial for methamphetamine use disorder.
“We are thrilled to have met the milestones set by the NIH’s Blueprint Neurotherapeutics Program and to be transitioning MT-110 into GMP manufacturing,” said Dr. Pat Griffin, co-founder of Myosin Therapeutics. “This accomplishment reflects our team’s dedication and the innovation behind our therapeutic approach. We are grateful for the support of the NIH BPN program and excited to partner with MRI Global as we prepare for the IND submission and upcoming clinical trials.”
Myosin Therapeutics’ participation in the BPN program has allowed the company to leverage NIH’s comprehensive resources, including industry expertise and access to critical funding. With this support, MT-110 is on track to become the first clinically validated pharmacotherapy for methamphetamine use disorder, addressing a significant unmet medical need.
About Myosin Therapeutics
Myosin Therapeutics is a Jupiter, FL-based biotechnology company spun out of the Wertheim UF Scripps Institute (formerly Scripps Research, Florida). The company is focused on developing therapies for oncology and central nervous system indications with a platform for targeting molecular nanomotor proteins. Myosin’s lead programs for glioblastoma and stimulant use disorder target non-muscle myosin II motor proteins.
About MRI Global
MRI Global is a leading research organization providing contract research and development services in the areas of national security, health, and life sciences. Their extensive experience in GMP manufacturing supports the production of clinical trial materials with a focus on safety, quality, and regulatory compliance.
For more information, email contact@myosintherapeutics.com
